Blood Preservation and Storage Methods Explained

Donated blood does not stay usable on its own for long. Without chemical preservatives and careful temperature control, a bag of whole blood would begin breaking down within hours, making it dangerous to transfuse. Modern preservation methods stretch the shelf life of red blood cells to about five to seven weeks, platelets to roughly five to seven days, and frozen plasma to a year or more. Each blood component has its own storage quirks, failure modes, and emerging technologies aimed at doing better. The science behind keeping blood viable after it leaves a donor’s veins is more complex than most people realize, and getting it wrong has real consequences for patients.

Why Blood Gets Split Into Parts

A unit of whole blood is a mix of red blood cells, white blood cells, platelets, and plasma, each with different storage needs. Hospitals almost never transfuse whole blood as-is. Instead, blood banks separate it into packed red blood cells, platelet concentrates, fresh frozen plasma, and cryoprecipitate using sequential rounds of centrifugation.¹ Spinning the bag at different speeds and durations pushes the heavier red cells to the bottom and the lighter plasma to the top, with platelets settling in a middle layer.² Splitting them apart matters because red cells need to be refrigerated, platelets need to stay near room temperature, and plasma needs to be frozen. Trying to store all three in one bag at one temperature would ruin at least one of them within a day or two.

Keeping Red Blood Cells Alive in a Bag

Red blood cells are the workhorses of transfusion medicine. Their job is carrying oxygen, and keeping them functional outside the body requires a carefully designed chemical bath. Every bag of donated blood is collected into a solution containing an anticoagulant (to prevent clotting) and nutrients that feed the cells during storage. The earliest versions of these solutions allowed storage for only a couple of weeks, but modern additive solutions have pushed that window to five to seven weeks while ensuring that the vast majority of collected units reach a patient before expiring.³

The standard additive solution used in many countries goes by the abbreviation SAGM, which stands for saline-adenine-glucose-mannitol. It works, but researchers have been refining the recipe. Newer formulations like PAGGSM and SOLX (also called AS-7) do a better job preserving the cell’s energy currency, ATP, and keeping the cells able to release oxygen efficiently. In one comparison, red cells stored in SOLX lost their ability to unload oxygen about half as fast as cells stored in SAGM, with a measurable difference emerging by the third week of storage.⁴ That matters because a red cell that holds onto its oxygen too tightly is not doing its job once it enters a patient’s bloodstream.

What Happens to Red Cells During Storage

Even under ideal conditions, stored red blood cells slowly degrade. Transfusion scientists call this collection of changes the “storage lesion,” and it involves a cascade of problems that worsen with time. The cells gradually lose key molecules like 2,3-DPG (which helps them release oxygen to tissues), ATP (their energy supply), and nitric oxide. As these molecules drop, the cells become stiffer and less able to squeeze through tiny capillaries.⁵ The cell membrane also takes a hit. Proteins embedded in the membrane change structure over time, and the cells begin shedding tiny membrane fragments called microvesicles.⁶

Studies of red cells stored for 35 days in standard anticoagulant found that roughly 16% of the membrane’s cholesterol and about 5% of its structural fats were shed as vesicles over that period.⁷ These vesicles accumulate in the bag and get transfused along with the red cells, potentially triggering inflammation in the recipient. The good news is that most of the storage lesion reverses once the cells are transfused into a living person. The 2,3-DPG levels, for instance, recover within hours to days after transfusion. But whether the oldest permissible units cause clinical harm compared to fresher ones has been one of transfusion medicine’s most debated questions.

Does Older Blood Hurt Patients?

Animal studies and small observational reports have raised alarms about old blood. Research in mice found that transfused older red cells increased mortality, caused more cell breakdown inside the body, and released free hemoglobin that interfered with blood vessel function.⁸ These findings are concerning in theory. But the large human trials have been consistently reassuring. A major randomized trial comparing red cells stored for an average of about 12 days against cells stored for about 22 days in critically ill adults found no significant difference in 90-day mortality between the two groups.⁹

A meta-analysis pooling data from thousands of patients confirmed that transfusing fresher red cells does not reduce overall or in-hospital mortality compared with standard-issue older cells.¹⁰ The evidence is strong enough that most blood banks no longer try to prioritize freshness for routine transfusions. They follow a first-in, first-out system, issuing the oldest available unit to minimize waste. The biology of the storage lesion is real, but it does not translate into detectable patient harm within the approved storage window for the typical recipient. There may be specific scenarios where storage age matters more, but proving it has been surprisingly difficult.

Platelet Storage and the Bacterial Problem

Platelets are the component that gives blood banks the biggest logistical headache. Unlike red cells, platelets must be stored at room temperature (around 20–24°C) with constant gentle agitation. They lose function rapidly when refrigerated because cold temperatures activate them prematurely, shortening their lifespan once transfused. But storing any biological product at room temperature is an open invitation for bacteria. Platelet concentrates are the blood component most commonly implicated in transfusion-transmitted bacterial infections, and current guidelines limit their shelf life to five days after collection precisely because of contamination risk.¹¹

Research has shown that live platelets at room temperature actually accelerate bacterial growth through their own metabolism. Bacteria multiplied exponentially faster in the presence of metabolically active platelets than in platelet-free plasma. Refrigeration controlled bacterial growth effectively, which has renewed interest in cold-stored platelets for specific clinical settings.¹¹ A randomized trial of cold-stored platelets given early to severely injured trauma patients found a trend toward lower 24-hour mortality compared with standard care, though the difference was not statistically significant.¹² In laboratory flow models simulating bleeding injuries, cold-stored platelets retained their clot-forming ability through day seven and were better at recruiting surrounding platelets in a low-platelet-count scenario than room-temperature products.¹³

Military settings have pushed cold-stored platelets furthest into real-world use. A safety analysis of cold-stored platelets used in combat trauma found survival comparable to room-temperature products, with clear logistical advantages in austere environments where maintaining a room-temperature agitator is impractical.¹⁴ Cold storage does not eliminate the tradeoffs entirely. Cold-activated platelets are cleared from the bloodstream faster than room-temperature ones, so they are better suited to active bleeding than to preventing future bleeds in patients with dangerously low platelet counts. The field is still sorting out which patients benefit most from which approach.

How Plasma and Cryoprecipitate Are Preserved

Plasma is the liquid portion of blood, rich in clotting factors, albumin, and antibodies. Preserving those proteins requires freezing. Fresh frozen plasma is separated from whole blood and frozen rapidly, typically at –30°C or colder, within hours of collection. Stored frozen, it remains viable for up to a year. The critical step is not just the freezing but the thawing: plasma is brought back to a liquid state in a water bath or specialized device at 37°C, a process that takes around 30 minutes for a standard bag.¹⁵ Once thawed, plasma can be kept at refrigerator temperature for up to five days for transfusion, though clotting factor levels decline gradually during that window.¹⁶

Newer thawing technology is addressing a persistent bottleneck in emergency rooms. Traditional water baths work but carry a small risk of contaminating the bag’s ports and require monitoring. A dry tempering system that presses bags between heated aluminum panels at 45°C thaws plasma as quickly as a water bath while eliminating the contamination risk. Testing confirmed it maintained clotting factor activity with no sign of protein damage.¹⁷ In trauma and massive hemorrhage, the 30 minutes it takes to thaw plasma can feel like an eternity. Any shaving of that time has direct implications for patient outcomes.

Cryoprecipitate is derived from plasma by slow thawing at cold temperatures, which causes certain proteins — primarily fibrinogen and factor VIII — to precipitate out as a concentrated paste. It is refrozen for storage and has a shelf life similar to plasma. Its main clinical use is replacing fibrinogen during massive bleeding or treating specific clotting disorders.

Freezing Red Cells for Rare Blood Types

Standard refrigerated storage works for most red cell units, but some situations call for much longer preservation. Patients with rare blood types may need cells that are collected only a handful of times a year worldwide. For these units, cryopreservation with glycerol allows storage at –65°C or colder for a decade or more.¹⁸ The glycerol acts as a biological antifreeze, preventing ice crystals from forming inside the cells and shredding their membranes. When a frozen unit is needed, it is thawed and then washed through decreasing salt concentrations to remove the glycerol before transfusion.

The process is labor-intensive and expensive, which is why it is reserved for genuinely rare phenotypes rather than routine inventory. Recent work has shown that pediatric-sized split units can be successfully cryopreserved using automated systems, which reduces the number of donors a child with a rare blood type is exposed to over a series of transfusions.¹⁹

Killing Pathogens Without Killing the Blood

Even with rigorous donor screening and testing, the risk of transfusion-transmitted infection is not zero. Pathogen reduction technologies aim to inactivate viruses, bacteria, and parasites in donated blood before it reaches the patient. The most widely adopted system combines a light-sensitive chemical called amotosalen with ultraviolet A light. This treatment damages the genetic material of pathogens, stopping them from replicating. Across testing against dozens of pathogens, the amotosalen-UVA system reduced infectious loads by at least 10,000-fold for most enveloped viruses and parasites in both plasma and platelet concentrates.²⁰

A separate approach uses riboflavin (vitamin B2) combined with UV light, which has been shown to eliminate Ebola virus to undetectable levels in both whole blood and serum without destroying protective antibodies in the plasma.²¹ These technologies represent a shift from the old “test and discard” model toward a “treat everything” approach. They are especially valuable in regions where emerging infections circulate and donor testing may lag behind newly identified threats. The tradeoff is cost and some loss of component quality, particularly for platelets and red cells, which can sustain some damage from the treatment process.

The Cold Chain and Where It Breaks

None of the chemistry matters if the temperature goes wrong between the blood bank and the patient’s bedside. Red cells must stay between 1°C and 6°C during storage and transport. A cross-sectional study that tracked over 121,000 temperature readings across a hospital’s blood supply chain found that about 10% of recorded temperatures fell outside the acceptable range.²² The majority of those deviations occurred inside the blood bank itself, not during transport. Some readings went as low as 0°C (risking freezing and cell rupture) and as high as 19.5°C (allowing metabolic deterioration and potential bacterial growth).²²

Validation studies of delivery systems that pack blood bags with ice packs in validated ratios have demonstrated that temperature can be maintained during transport under different ambient conditions.²³ The challenge is human judgment. Staff at many facilities still assess blood bag temperature by touch or visual inspection, which is subjective and unreliable. Automated temperature monitoring devices that travel with the blood bag provide an objective record and catch deviations that a person would miss.

Blood Waste and Why It Matters

Blood is a limited, perishable resource, and waste is a persistent problem. A retrospective analysis at a teaching hospital found that the leading cause of discarded blood was excessive ordering: clinicians requested more units than the patient ultimately needed, and the surplus expired or could not be reissued in time. That single cause accounted for roughly a fifth of all wasted units. Other significant causes included ordering errors, patients dying or being discharged before transfusion, and platelet units ruined by improper storage temperatures.²⁴ Accidental puncture of blood bags during handling was another preventable source of loss. Given that blood shortages are a recurring crisis in many health systems, reducing waste through better ordering algorithms, staff training, and inventory management is one of the lowest-cost ways to stretch the available supply.

Not All Donors’ Blood Stores the Same Way

One underappreciated aspect of blood storage is that donor biology creates real variation in how well a unit holds up over weeks in a bag. Researchers have investigated whether the donor’s age, sex, and genetic makeup influence the severity of the storage lesion. While early observational studies suggested that sex mismatches between donor and recipient or donor age might affect outcomes, follow-up analyses have questioned those findings, and the picture remains unsettled.²⁵

Genetics offers a more concrete lead. A study of over 13,000 donors identified a common variant in a gene called PCMT1 that influenced how well red cells tolerated storage. Donors carrying a particular version of this gene, more common among people of Asian or African ancestry, showed lower rates of a type of storage-related cell damage. Their red cells had higher levels of a repair enzyme that helps fix damaged proteins.²⁶ This line of research is still early, but it raises the possibility that blood banks could one day match donors to storage strategies based on genetic profiles, getting more usable shelf life from some units and flagging others for faster use.

Special Concerns for Small Patients

Newborns and young children are disproportionately vulnerable to certain storage-related problems. Potassium leaks out of red cells during storage, and the older the unit, the higher the potassium concentration in the surrounding fluid. For an adult, this extra potassium is diluted by their large blood volume and cleared quickly by the kidneys. For a tiny infant receiving a relatively large transfusion relative to body size, especially if the blood is pushed rapidly through a line, the potassium load can spike to dangerous levels. Irradiation of blood products, often done for immunocompromised patients, worsens the potassium leak further.²⁷ Pediatric transfusion protocols often specify fresher units and slower infusion rates to manage this risk, one of the few clinical scenarios where storage age has clear practical consequences.

Freeze-Dried Plasma and the Future of Battlefield Blood

One of the most active areas of development in blood preservation is freeze-dried plasma. The concept is simple: remove the water from frozen plasma to produce a lightweight powder that is shelf-stable at room temperature for extended periods and can be reconstituted with sterile water in minutes. This eliminates the need for freezers and thawing equipment, making plasma available in places where traditional cold-chain logistics are impossible.²⁸

For decades, freeze-dried plasma was available in only a handful of countries, mainly France and Germany, which produced it for military use. Recently, a commercially manufactured product called OctaplasLG Powder was approved in 17 countries and authorized for emergency use by the U.S. and Canadian militaries.²⁹ Military planners are particularly interested because future conflicts may involve longer evacuation times to medical facilities, increasing the window during which a wounded person needs resuscitation products that do not require refrigeration.

Lab-Grown Red Cells and Artificial Oxygen Carriers

Two futuristic approaches aim to reduce or eliminate dependence on human donors altogether. The first is growing red blood cells in the lab from stem cells. Researchers have generated red cells from cord blood stem cells and from induced pluripotent stem cells, and early animal studies have shown that these lab-grown cells can mature and function after being infused into living recipients.³⁰ Lab-grown cells from stem cell lines could theoretically provide an unlimited, pathogen-free, universally compatible blood supply. But they are nowhere near clinical scale. Current culture systems produce cells that resemble immature red cells more than fully mature ones, with slightly impaired flexibility compared to normal cells.³¹ A small human trial in the U.K. infused lab-grown red cells into volunteers for the first time in 2022, but manufacturing enough cells for a single standard transfusion remains prohibitively expensive and slow.

The second approach is hemoglobin-based oxygen carriers, essentially free-floating hemoglobin molecules engineered to carry oxygen without being packed inside a cell. These have been in development for decades using cross-linked, polymer-wrapped, and encapsulated forms of hemoglobin.³² The appeal is enormous: a shelf-stable, room-temperature product that works regardless of blood type. But the reality has been discouraging. Free hemoglobin outside a cell scavenges nitric oxide, causing blood vessels to constrict and driving up blood pressure. It also generates reactive molecules that damage tissues. Multiple large clinical trials have shown elevated rates of adverse events, and no hemoglobin-based oxygen carrier has received FDA approval for clinical use in the United States.³³ Researchers continue refining the concept, but a safe, effective artificial blood substitute remains an elusive goal.

Quality Control Across Different Regulatory Systems

What counts as an acceptable unit of red blood cells depends on which country’s standards apply. In the United States, guidelines set a minimum hemoglobin content of 45 grams per unit, with hematocrit values varying by the additive solution used (roughly 55–85%). European standards specify a similar hemoglobin minimum but cap acceptable hemolysis at the end of the storage period at less than 8% of the red cell mass. Egyptian national standards, by comparison, focus on a target volume of about 280 mL and a hematocrit range of 60–75%.³⁴ These variations mean that a unit meeting quality standards in one country might technically fail in another, though the clinical consequences of these differences are generally minor. What matters across all systems is that the cells are not visibly breaking down, the bag is sterile, and the hemoglobin content is high enough to deliver meaningful oxygen-carrying capacity to the patient.

1
PubMed Central. Overview of blood components and their preparation
2
PubMed. Blood component separation of pathogen-reduced whole blood by the PRP method produces acceptable red cells but platelet yields and function are diminished
3
PubMed. An update on solutions for red cell storage
4
PubMed Central. Rapid oxygen release from stored red blood cells can be preserved for longer with refined additive solutions
5
PubMed Central. Red blood cell storage lesion
6
PubMed Central. Proteomics of Stored Red Blood Cell Membrane and Storage-Induced Microvesicles Reveals the Association of Flotillin-2 With Band 3 Complexes
7
PubMed. Erythrocyte membrane vesiculation and changes in membrane composition during storage in citrate-phosphate-dextrose-adenine-1
8
PubMed Central. Transfusion of fresh vs. older red blood cells in the context of infection
9
PubMed. Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults
10
PubMed. Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis
11
Blood. Platelet Lactate Production during Room Temperature Storage Promotes Bacterial Growth
12
PubMed Central. Early Cold Stored Platelet Transfusion Following Severe Injury A Randomized Clinical Trial
13
PubMed Central. Microfluidic transection injury and high-shear thrombus formation demonstrate increased hemostatic efficacy of cold-stored platelets and in vitro resuscitation in induced coagulopathy models
14
PubMed. A safety and feasibility analysis on the use of cold-stored platelets in combat trauma
15
PubMed Central. The effect of repeated freezing and thawing on levels of vitamin K-dependent coagulation factors and fibrinogen in fresh frozen plasma
16
Hematology, Transfusion and Cell Therapy. Coagulation factor stability and sterility of thawed fresh frozen plasma stored at 2-6 °C for five days: Towards optimizing utilization
17
PubMed. Rapid thawing of fresh frozen plasma with a 45°C dry tempering system maintains critical coagulation activities
18
Immunohematology. Freezing and recovering rare red blood cells using glycerol
19
PubMed. A novel protocol for cryopreservation of paediatric red blood cell units allows increased availability of rare blood types
20
PubMed Central. Inactivation of a broad spectrum of viruses and parasites by photochemical treatment of plasma and platelets using amotosalen and ultraviolet A light
21
PubMed Central. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro
22
PubMed Central. Monitoring of Storage and Transportation Temperature Conditions in Red Blood Cell Units: A Cross-Sectional Study
23
Indonesian Journal of Blood And Transfusion. Validation of the Cold Chain Product (CCP) delivery process for whole blood
24
PubMed Central. Trends in blood transfusion and causes of blood wastage: a retrospective analysis in a teaching hospital
25
Transfusion and Apheresis Science. It’s in your blood: The impact of age, sex, genetic factors and exposures on stored red blood cell metabolism
26
PubMed Central. Improved red blood cell storage quality of blood from donors carrying the hypermorphic PIMT I120 variant
27
PubMed. Transfusion-associated hyperkalemia in pediatric population: Prevalence, risk factors, survival, infusion rate, and RBC unit features
28
Transfusion Medicine Reviews. Prehospital Freeze-Dried Plasma in Trauma: A Critical Review
29
PubMed. Potential military applications for a new freeze-dried plasma
30
PubMed Central. Tracing the in vivo behavior of nucleated cultured red blood cells generated from hematopoietic stem and progenitor cells
31
PubMed Central. Membrane Properties of Human Induced Pluripotent Stem Cell-Derived Cultured Red Blood Cells
32
PubMed Central. Hemoglobin-based Oxygen Carriers: Current State-of-the-art and Novel Molecules
33
PubMed Central. Artificial Oxygen Carriers: Lessons From Hemoglobin-Based Oxygen Carrier Clinical Trials and Current Development Efforts
34
PubMed Central. Internal quality assessment of blood components at Mansoura university blood transfusion center